Preparation of vitexin albumin nanoparticles and its pharmacokinetic study / 中国中药杂志

This study aims to prepare vitexin albumin nanoparticles(VT-BSA-NPs) to alleviate the low bioavailability of vitexin(VT) in vivo due to its poor water solubility. VT micro powders were prepared by the antisolvent crystallization method, and the morphology, size, and physicochemical properties of VT micro powders were studied. The results showed that the VT micro powder had a particle size of(187.13±7.15) nm, an approximate spherical morphology, and a uniform size distribution. Compared with VT, the chemical structure of VT micro powders has not changed. VT-BSA-NPs were prepared from VT micro powders by desolvation-crosslinking curing method. The preparation process was screened by single factor test and orthogonal test, and the quality evaluation of the optimal prescription particle size, PDI, Zeta potential, EE, and morphology was performed. The results showed that the average particle size of VT-BSA-NPs was(124.33±0.47) nm; the PDI was 0.184±0.012; the Zeta potential was(-48.83±2.20) mV, and the encapsulation rate was 83.43%±0.39%, all of which met the formulation-related requirements. The morphological results showed that the VT-BSA-NPs were approximately spherical in appearance, regular in shape, and without adhesion on the surface. In vitro release results showed a significantly reduced release rate of VT-BSA-NPs compared with VT, indicating a good sustained release effect. LC-MS/MS was used to establish an analytical method for in vivo analysis of VT and study the plasma pharmacokinetics of VT-BSA-NPs in rats. The results showed that the specificity of the analytical method was good, and the extraction recovery was more than 90%. Compared with VT and VT micro powders, VT-BSA-NPs could significantly increase AUC, MRT, and t_(1/2), which was beneficial to improve the bioavailability of VT.

Effect of salmeterol/fluticasone propionate combined with lip shrinkage respiration on the treatment of pneumoconiosis complicated COPD / 中国职业医学

OBJECTIVE: To observe the effects of combined treatment using salmeterol / fluticasone propionate and lip shrinkage respiration on the treatment of patients with pneumoconiosis complicated with chronic obstructive pulmonary disease( COPD). METHODS: By random number table method,98 patients with stable pneumoconiosis complicated with COPD were divided into 3 groups: drug treatment group( 33 cases) was treated only with inhalation of salmeterol /fluticasone propionate( 50 μg /500 μg),twice a day; lip shrinkage respiration group( 34 cases) was treated with abdominal breathing and lip shrinkage respiration training,three times daily for 15 min per session; combined treatment group( 31 cases) was treated with both the above treatments. Before and after 6 months of treatment,the lung function,the 6-minute walk distance and the oxygen saturation( Sa O2) were detected. The modified Medical Research Council( m MRC) Respiratory Questionnaire was used to evaluate the degree of dyspnea. RESULTS: After 6 months of treatment,the forced vital capacity percentage( FVC%),percentage of forced expiratory volume in one second( FEV1%),maximum ventilatory volume( MVV),6-minute walking distance,m MRC degree and the Sa O2 improved in the patients of these 3groups compared with those before treatment( P < 0. 05). Compared with the drug treatment group or lip shrinkage respiration group after treatment,the FVC%,FEV1%,MVV,6-minute walking distance and the Sa O2 in the combined treatment group were higher( P < 0. 05),and the m MRC degree was lower( P < 0. 05). CONCLUSION: Salmeterol /fluticasone propionate combined with lip shrinkage respiration treatment had better therapeutic effect than single treatment in treating patients with pneumoconiosis combined with COPD.

Gene transfer into porcine myocardium via pericardial cavity by homemade easy puncture device / 中国医学科学杂志(英文版)

<p><b>OBJECTIVE</b>To explore the feasibility and safety of gene transfer into porcine myocardium via the pericardial cavity by a homemade easy device.</p><p><b>METHODS</b>Replication-deficient recombinant adenoviral vector carrying LacZ report gene (Ad-LacZ) was constructed by the calcium phosphate precipitation method. Twelve healthy Chinese mini-swine were randomly divided into experimental group (n = 6) and control group (n = 6). Acute myocardial infarction (AMI) model was established by balloon occlusion of the distal part of D1 branch of left anterior descending (LAD) artery, at the same time the intrapericardial cavity injections were performed through the small incision of the abdominal wall below the xyphoid appendix using a homemade device. Then gene transfer was performed using a central venous catheter. The pericardium was pretreated with injection of a mixture of collagenase (1,200 U) and hyaluronidase (3,000 U) in both groups. Then 2.0 x 10(9) plaque formation unit (PFU) Ad-LacZ was injected into the pericardial cavity in experimental group, while 1 mL of normal saline was injected in the control group. The beta-galactosidase activity detection and X-gal staining of the ischemic myocardium were performed on the 3rd, 7th, and 28th day after injection.</p><p><b>RESULTS</b>The LAD artery was occluded completely and infarction and ischemia were detected by histological assessment In experimental group, the X-gal staining positive cells and beta-galactosidase activity quantification were detectable on the 3rd day after injection, increased markedly on the 7th day, and then declined on the 28th day. The transfer efficiencies indicated by the positive myocardial cells were 16.7%, 45.6% , 22.8% on the 3rd, 7th, 28th day, respectively. In control group, no positive cells and beta-galactosidase activity were observed.</p><p><b>CONCLUSION</b>Adenovirus can be transferred into ischemic myocardium and express target gene in the AMI model for four weeks with the homemade easy device via pericardial cavity pretreated by collagenase and hyaluronidase.</p>